AR105568A1 - Un método para provocar una respuesta inmunitaria en un sujeto receptor de especie porcina - Google Patents
Un método para provocar una respuesta inmunitaria en un sujeto receptor de especie porcinaInfo
- Publication number
- AR105568A1 AR105568A1 ARP160102348A ARP160102348A AR105568A1 AR 105568 A1 AR105568 A1 AR 105568A1 AR P160102348 A ARP160102348 A AR P160102348A AR P160102348 A ARP160102348 A AR P160102348A AR 105568 A1 AR105568 A1 AR 105568A1
- Authority
- AR
- Argentina
- Prior art keywords
- pig
- immunomodulatory composition
- nucleic acid
- administering
- cholesterol
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 9
- 230000028993 immune response Effects 0.000 title abstract 2
- 241000894007 species Species 0.000 title abstract 2
- 230000002519 immonomodulatory effect Effects 0.000 abstract 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 8
- 150000007523 nucleic acids Chemical group 0.000 abstract 6
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 4
- 235000012000 cholesterol Nutrition 0.000 abstract 4
- 230000003308 immunostimulating effect Effects 0.000 abstract 4
- 239000002502 liposome Substances 0.000 abstract 4
- 125000002091 cationic group Chemical group 0.000 abstract 3
- 239000003981 vehicle Substances 0.000 abstract 3
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 2
- 206010012735 Diarrhoea Diseases 0.000 abstract 2
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 abstract 2
- 241000282887 Suidae Species 0.000 abstract 2
- -1 cationic lipid Chemical class 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 239000002955 immunomodulating agent Substances 0.000 abstract 2
- 230000002584 immunomodulator Effects 0.000 abstract 2
- 229940121354 immunomodulator Drugs 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 230000000638 stimulation Effects 0.000 abstract 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 abstract 1
- BDUUGQJHZOBJBT-CLFAGFIQSA-N 2-[3-(2-hydroxyethyl)-2-[(Z)-octadec-9-enyl]imidazolidin-1-yl]ethyl (Z)-octadec-9-enoate Chemical compound C(CCCCCCC\C=C/CCCCCCCC)(=O)OCCN1C(N(CC1)CCO)CCCCCCCC\C=C/CCCCCCCC BDUUGQJHZOBJBT-CLFAGFIQSA-N 0.000 abstract 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 abstract 1
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 239000003124 biologic agent Substances 0.000 abstract 1
- 229960001438 immunostimulant agent Drugs 0.000 abstract 1
- 239000003022 immunostimulating agent Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- SZYJELPVAFJOGJ-UHFFFAOYSA-N trimethylamine hydrochloride Chemical compound Cl.CN(C)C SZYJELPVAFJOGJ-UHFFFAOYSA-N 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Reivindicación 1: Un método para provocar una respuesta inmunitaria en un sujeto receptor de especie porcina que comprende: administrar una cantidad efectiva de una composición inmunomoduladora a un sujeto de la especie porcina, donde la composición inmunomoduladora comprende una secuencia de ácidos nucleicos que comprende al menos un motivo CpG inmunoestimulante, al menos un motivo CpG no inmunoestimulante y un liposoma catiónico. Reivindicación 3: El método de reivindicación 1, donde el vehículo de suministro de liposoma comprende pares de lípidos que se seleccionan del grupo que consiste en cloruro de N-[1-(2,3-dioleiloxi)propil]-N,N,N-trimetilamonio (DOTMA) y colesterol; cloruro de N-[1-(2,3-dioleiloxi)propil]-N,N,N-trimetilamonio (DOTAP) y colesterol; cloruro de 1-[2-(oleoyloxi)etil]-2-oleil-3-(2-hidroxietil)imidazolinio (DOTIM) y colesterol; y bromuro dedimetildioctadecilamonio (DDAB) y colesterol. Reivindicación 4: El método de la reivindicación 1, donde la composición inmunomoduladora comprende adicionalmente o se administra en combinación con un agente biológico. Reivindicación 7: El método de la reivindicación 1, donde la composición inmunomoduladora comprende una secuencia de ácido nucleico con al menos 80% de identidad de secuencia con una secuencia que se selecciona del grupo que consiste en SEQ ID Nº 1, SEQ ID Nº 2, SEQ ID Nº 3 y SEQ ID Nº 4. Reivindicación 11: Un método para mejorar la producción de porcinos de granja que comprende administrar a un porcino una composición inmunomoduladora, donde la composición inmunomoduladora comprende una secuencia de ácidos nucleicos que comprende al menos un motivo CpG inmunoestimulante y un liposoma catiónico. Reivindicación 12: Un método para mejorar la supervivencia de porcinos de granja que comprende administrar a un porcino una composición inmunomoduladora, donde la composición inmunomoduladora comprende una secuencia de ácidos nucleicos que comprende al menos un motivo CpG inmunoestimulante y un liposoma catiónico. Reivindicación 13: Un método para reducir la diarrea en un cerdo que comprende administrar al cerdo una cantidad eficaz de una composición inmunomoduladora, donde el inmunomodulador comprende: a) un vehículo de suministro de lípidos catiónicos; y b) una molécula de ácido nucleico que no codifica un inmunógeno, donde tal administración reduce la diarrea en tal cerdo luego de una estimulación con Escherichia coli. Reivindicación 19: Un método para aumentar el aumento de peso en un cerdo que comprende administrar al cerdo una composición inmunomoduladora, donde el inmunomodulador comprende: a) un vehículo de suministro de lípidos catiónicos; y b) una molécula de ácido nucleico que no codifica un inmunógeno, donde tal administración aumenta el peso de tal cerdo luego de una estimulación con el virus de síndrome respiratorio y reproductivo porcino (PRRSV).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199848P | 2015-07-31 | 2015-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105568A1 true AR105568A1 (es) | 2017-10-18 |
Family
ID=56682095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102348A AR105568A1 (es) | 2015-07-31 | 2016-08-01 | Un método para provocar una respuesta inmunitaria en un sujeto receptor de especie porcina |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11439703B2 (es) |
| EP (1) | EP3328424A1 (es) |
| JP (1) | JP2018521109A (es) |
| KR (1) | KR20180036765A (es) |
| CN (1) | CN108025062A (es) |
| AR (1) | AR105568A1 (es) |
| AU (1) | AU2016302436B2 (es) |
| CA (1) | CA2993883A1 (es) |
| CL (1) | CL2018000253A1 (es) |
| HK (1) | HK1255052A1 (es) |
| IL (1) | IL256984A (es) |
| MX (1) | MX2018001251A (es) |
| PH (1) | PH12018500201A1 (es) |
| SG (1) | SG10202000891UA (es) |
| TW (1) | TW201718001A (es) |
| WO (1) | WO2017021266A1 (es) |
| ZA (1) | ZA201801338B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017301528A1 (en) | 2016-07-26 | 2019-02-14 | Elanco Animal Health Gmbh | Increased fertility in bovine species |
| WO2022072910A1 (en) * | 2020-10-02 | 2022-04-07 | Celsion Corporation | Polynucleotide vaccines and methods of using the same |
| EP4526328A1 (en) * | 2022-05-17 | 2025-03-26 | Elanco US Inc. | Methods for predicting efficacy of a modified live porcine reproductive and respiratory syndrome virus (prrsv) vaccine |
| CN118615451A (zh) * | 2024-06-25 | 2024-09-10 | 武汉合生科技有限公司 | 针对蓝耳病毒的新型药物 |
| CN121102495A (zh) * | 2025-11-17 | 2025-12-12 | 联合钠米(天津)科技有限公司 | 一种基于二烃基咪唑阳离子脂质的核酸药物制剂及其制备方法与应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| ATE370740T1 (de) * | 1997-05-20 | 2007-09-15 | Ottawa Health Research Inst | Verfahren zur herstellung von nukleinsäurekonstrukten |
| US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| US20040247662A1 (en) | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
| US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| US6586409B1 (en) | 1999-03-26 | 2003-07-01 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
| HU221664B1 (hu) * | 1999-03-31 | 2002-12-28 | MTA Állatorvostudományi Kutatóintézete | Élő, szájon át adható Escherichia coli vakcina készítésére alkalmas törzs a sertések választási hasmenésének megelőzésére és a törzs előállítására alkalmas eljárás |
| US20040002472A1 (en) | 2000-01-21 | 2004-01-01 | Audonnet Jean-Christophe Francis | Vaccination or immunization using a prime-boost regimen |
| DE60227157D1 (de) * | 2001-02-13 | 2008-07-31 | Us Gov Sec Army | Impstoffe zur transkutanen immunisierung gegen reisediarrhö |
| PL1605971T3 (pl) | 2003-03-26 | 2010-10-29 | Wyeth Llc | Kompozycja immunogenna i sposoby |
| JP2007509040A (ja) | 2003-10-11 | 2007-04-12 | イネックス ファーマシューティカルズ コーポレイション | 先天性免疫及び抗体依存性細胞傷害を強化するための方法及び組成物 |
| US20050181035A1 (en) | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
| CA2577270A1 (en) | 2004-08-13 | 2006-02-16 | The Trustees Of The University Of Pennsylvania | Antibiotic resistance free dna vaccines |
| EP2249843A4 (en) * | 2008-02-24 | 2013-05-08 | Us Gov Health & Human Serv | USE OF IMMUNOGENIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF INFECTIONS BY DISEASES |
| JP5759890B2 (ja) | 2008-03-25 | 2015-08-05 | ジュバリス・バイオセラピューティクス・インコーポレイテッドＪｕｖａｒｉｓ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | カチオン性脂質−ｄｎａ複合体（ｃｌｄｃ）の投与による免疫応答の増強 |
| US8251111B2 (en) | 2008-09-18 | 2012-08-28 | Premium Balloon Accessories, Inc. | Balloon inflator |
| US8465748B2 (en) * | 2009-03-30 | 2013-06-18 | Matthias Giese | Vaccine compositions and methods containing an immunogen derived from equine arteritis virus |
| MX336019B (es) * | 2009-05-14 | 2016-01-06 | Bayer Ip Gmbh | Respuesta inmunitaria reforzada en especies aviares. |
| BR112013016231B1 (pt) | 2010-12-22 | 2021-03-23 | Bayer Intellectual Property Gmbh | Composição imunomoduladora para o tratamento de doença respiratória bovina |
| CA2940794C (en) * | 2014-02-28 | 2022-05-31 | Bayer Animal Health Gmbh | Immunostimulatory plasmids |
-
2016
- 2016-07-28 AU AU2016302436A patent/AU2016302436B2/en active Active
- 2016-07-28 HK HK18114176.7A patent/HK1255052A1/zh unknown
- 2016-07-28 JP JP2018504671A patent/JP2018521109A/ja active Pending
- 2016-07-28 SG SG10202000891UA patent/SG10202000891UA/en unknown
- 2016-07-28 MX MX2018001251A patent/MX2018001251A/es unknown
- 2016-07-28 US US15/748,444 patent/US11439703B2/en active Active
- 2016-07-28 CA CA2993883A patent/CA2993883A1/en not_active Abandoned
- 2016-07-28 WO PCT/EP2016/067971 patent/WO2017021266A1/en not_active Ceased
- 2016-07-28 EP EP16750416.6A patent/EP3328424A1/en not_active Withdrawn
- 2016-07-28 TW TW105123924A patent/TW201718001A/zh unknown
- 2016-07-28 KR KR1020187006085A patent/KR20180036765A/ko not_active Withdrawn
- 2016-07-28 CN CN201680057074.6A patent/CN108025062A/zh active Pending
- 2016-08-01 AR ARP160102348A patent/AR105568A1/es unknown
-
2018
- 2018-01-17 IL IL256984A patent/IL256984A/en unknown
- 2018-01-25 PH PH12018500201A patent/PH12018500201A1/en unknown
- 2018-01-29 CL CL2018000253A patent/CL2018000253A1/es unknown
- 2018-02-27 ZA ZA2018/01338A patent/ZA201801338B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201801338B (en) | 2021-08-25 |
| MX2018001251A (es) | 2018-03-26 |
| CL2018000253A1 (es) | 2018-07-20 |
| US20180326049A1 (en) | 2018-11-15 |
| HK1255052A1 (zh) | 2019-08-02 |
| SG10202000891UA (en) | 2020-03-30 |
| TW201718001A (zh) | 2017-06-01 |
| IL256984A (en) | 2018-03-29 |
| PH12018500201A1 (en) | 2018-07-30 |
| US11439703B2 (en) | 2022-09-13 |
| CN108025062A (zh) | 2018-05-11 |
| EP3328424A1 (en) | 2018-06-06 |
| WO2017021266A1 (en) | 2017-02-09 |
| CA2993883A1 (en) | 2017-02-09 |
| KR20180036765A (ko) | 2018-04-09 |
| BR112018002107A2 (pt) | 2018-09-25 |
| AU2016302436A1 (en) | 2018-02-15 |
| AU2016302436B2 (en) | 2022-03-03 |
| JP2018521109A (ja) | 2018-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105568A1 (es) | Un método para provocar una respuesta inmunitaria en un sujeto receptor de especie porcina | |
| RU2760790C2 (ru) | Способы получения одноцепочечной рнк | |
| US12458690B2 (en) | African swine fever virus vaccine | |
| ZA202101465B (en) | Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery | |
| US20190336608A1 (en) | Cationic carriers for nucleic acid delivery | |
| ES2722204T3 (es) | Respuesta inmune mejorada en especies bovinas | |
| EP4632075A3 (en) | Method for reducing immunogenicity of rna | |
| CO2018005229A2 (es) | Vacuna de virus sincitial respiratorio | |
| TWI589298B (zh) | 陽離子之脂質疫苗組合物及其使用方法 | |
| WO2015024668A2 (en) | Respiratory syncytial virus (rsv) vaccine | |
| WO2015149944A3 (en) | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant | |
| CL2020000295A1 (es) | Métodos de terapia génica del factor viii (fviii) | |
| JP2017512202A5 (es) | ||
| RU2016138321A (ru) | Иммуностимулирующие плазмиды | |
| ZA202310755B (en) | Immunogenic composition against influenza | |
| PE20200933A1 (es) | Composiciones inmunoestimulantes | |
| TW201427686A (zh) | 改良之疫苗組成物及使用方法 | |
| FI3244920T3 (fi) | Suu- ja sorkkatautirokote | |
| MX2023014901A (es) | Nanoparticulas que contienen acido nucleico. | |
| RU2014135522A (ru) | Промоторы для увеличенной экспрессии белка у менингококка | |
| WO2024044178A1 (en) | Lipid nanoparticle (lnp) composition or formulation for nucleic acid therapeutics | |
| CO2017001614A2 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
| US20240075128A1 (en) | Immunogenic constructs, compositions, and methods for inducing immune response | |
| JP2018518511A5 (es) | ||
| AR105160A1 (es) | Métodos de modulación de moléculas de vigilancia de adn citosólicas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |